Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Eupraxia’s CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

In a US study, patients with severe eosinophilic esophagitis (EoE) by Index of Severity for EoE had poor responses to topical corticosteroid therapy.

Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

Cedars-Sinai researchers have developed a novel nutritional formula, mBiota Elemental, a palatable elemental diet (PED) that ...

Apogee Therapeutics, Inc.’s APGE share price has surged by 5.14%, which has investors questioning if this is right time to ...

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. On April 24, 2025, Eupraxia Pharmaceuticals announced its participation in several ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.